ZA93779B - Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5. - Google Patents

Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.

Info

Publication number
ZA93779B
ZA93779B ZA93779A ZA93779A ZA93779B ZA 93779 B ZA93779 B ZA 93779B ZA 93779 A ZA93779 A ZA 93779A ZA 93779 A ZA93779 A ZA 93779A ZA 93779 B ZA93779 B ZA 93779B
Authority
ZA
South Africa
Prior art keywords
cloning
expression
design
monoclonal antibodies
antibodies against
Prior art date
Application number
ZA93779A
Other languages
English (en)
Inventor
Chuan-Chu Chou
John S Abrams
Mary E Petro
Stephen Tindall
Paul J Zavodny
Nicholas J Murgolo
Chung-Her Jenh
Jon E Silver
William T Windsor
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA93779B publication Critical patent/ZA93779B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA93779A 1992-02-06 1993-02-04 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5. ZA93779B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83284292A 1992-02-06 1992-02-06

Publications (1)

Publication Number Publication Date
ZA93779B true ZA93779B (en) 1993-08-05

Family

ID=25262763

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA93779A ZA93779B (en) 1992-02-06 1993-02-04 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.

Country Status (21)

Country Link
US (1) US6451982B1 (show.php)
EP (1) EP0625201A1 (show.php)
JP (2) JPH07505767A (show.php)
KR (2) KR0150060B1 (show.php)
CN (1) CN1077991A (show.php)
AR (1) AR248044A1 (show.php)
AU (1) AU683836B2 (show.php)
CA (1) CA2129445A1 (show.php)
CZ (1) CZ291039B6 (show.php)
FI (1) FI943635A7 (show.php)
HU (1) HUT67943A (show.php)
IL (1) IL104620A (show.php)
NO (1) NO942912L (show.php)
NZ (1) NZ249633A (show.php)
PL (1) PL176393B1 (show.php)
RU (1) RU94045919A (show.php)
SG (1) SG49597A1 (show.php)
SK (1) SK280610B6 (show.php)
TN (1) TNSN93012A1 (show.php)
WO (1) WO1993016184A1 (show.php)
ZA (1) ZA93779B (show.php)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104620A (en) 1992-02-06 2000-02-29 Schering Plough Corp Humanized monoclonal antibodies against human interleukin-5
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
ES2277336T3 (es) * 1994-12-23 2007-07-01 Smithkline Beecham Corporation Antagonistas de il-5 recombinantes utiles en el tratamiento de enfermadades mediadas por il-5.
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
DK1527100T3 (da) 2002-03-29 2009-09-07 Schering Corp Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
US7927840B2 (en) * 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
CA2501946C (en) * 2002-10-16 2014-12-23 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
MXPA05006384A (es) 2002-12-17 2005-08-29 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US8192736B2 (en) 2004-10-28 2012-06-05 Kyowa Hakko Kirin Co., Ltd Remedy for endometriosis
ES2732623T3 (es) 2005-01-06 2019-11-25 Innate Pharma Sa Tratamientos y métodos de combinación anti-KIR
CA2602375C (en) 2005-03-23 2018-07-24 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
SI2152290T1 (sl) 2007-04-30 2014-09-30 Glaxosmithkline Llc Postopki za dajanje anti-IL-5 protiteles
EP2274009B1 (en) 2008-03-28 2013-11-13 GlaxoSmithKline LLC Methods of treatment
MX2011003601A (es) * 2008-10-23 2011-04-27 Hoffmann La Roche Determinacion de acido nucleico que codifica inmunoglobulina.
ES2720136T3 (es) * 2010-12-22 2019-07-18 Teva Pharmaceuticals Australia Pty Ltd Anticuerpo modificado con semivida mejorada
WO2013087911A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9677018B2 (en) 2013-01-09 2017-06-13 Thyssenkrupp Industrial Solutions Ag Process for the production of synthesis gas from hard coal
RS60701B1 (sr) 2014-09-08 2020-09-30 Cephalon Inc Primena reslizumaba za tretman umerene do ozbiljne eozinofilne astme
PH12018500379B1 (en) 2015-08-24 2022-11-23 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
CN110913887A (zh) 2017-06-06 2020-03-24 葛兰素史克有限责任公司 用于儿科患者的生物药物组合物和方法
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
US11224653B2 (en) 2017-08-24 2022-01-18 Cephalon, Inc. Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
CN111065651B (zh) * 2017-09-29 2023-07-14 江苏恒瑞医药股份有限公司 Il-5抗体、其抗原结合片段及医药用途
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
JPH07563B2 (ja) * 1988-11-03 1995-01-11 シェリング・コーポレーション 好酸球増加症の予防または鎮静用薬剤
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2041271A1 (en) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
IL104620A (en) 1992-02-06 2000-02-29 Schering Plough Corp Humanized monoclonal antibodies against human interleukin-5

Also Published As

Publication number Publication date
CZ291039B6 (cs) 2002-12-11
KR0150060B1 (ko) 1998-08-17
SK91894A3 (en) 1995-02-08
HUT67943A (en) 1995-05-29
SK280610B6 (sk) 2000-05-16
SG49597A1 (en) 1998-06-15
JPH07505767A (ja) 1995-06-29
CN1077991A (zh) 1993-11-03
FI943635L (fi) 1994-08-05
PL176393B1 (pl) 1999-05-31
WO1993016184A1 (en) 1993-08-19
TNSN93012A1 (fr) 1994-03-17
AR248044A1 (es) 1995-05-31
US6451982B1 (en) 2002-09-17
KR950700413A (ko) 1995-01-16
FI943635A0 (fi) 1994-08-05
AU683836B2 (en) 1997-11-27
RU94045919A (ru) 1996-11-10
JP2000210097A (ja) 2000-08-02
IL104620A (en) 2000-02-29
NO942912L (no) 1994-10-06
AU3656093A (en) 1993-09-03
CA2129445A1 (en) 1993-08-07
HU9402293D0 (en) 1994-10-28
FI943635A7 (fi) 1994-08-05
NO942912D0 (show.php) 1994-08-05
CZ191094A3 (en) 1994-12-15
NZ249633A (en) 1995-12-21
IL104620A0 (en) 1993-06-10
EP0625201A1 (en) 1994-11-23

Similar Documents

Publication Publication Date Title
ZA93779B (en) Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.
ZA949341B (en) Humanized antibodies and uses thereof
AU1289795A (en) Monoclonal antibodies specific for human interleukin-5
EP0568631A4 (en) MONOCLONAL ANTIBODIES FOR A CELL SURFACE RECEPTOR (ELAM-1) AND USES THEREOF.
EP0578515A3 (en) Humanized monoclonal antibodies.
GB8910395D0 (en) Human monoclonal antibody and hybridoma producing the same
EP0683675A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST CYTOMEGALOVIRUS.
EP0506523A3 (en) Monoclonal antibodies
ZA9510195B (en) Monoclonal antibody fragments having immunosuppressant activity
EP0498767A3 (en) Chimeric antiidiotypic monoclonal antibodies
AU657504B2 (en) Antibody against human plasmin-alpha2-plasmin inhibitor complex, hybridoma and immunoassay
EP0554458A4 (en) Immunoassay, monoclonal antibody and hybridoma
HK1008833A (en) Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
PL323195A1 (en) Alpha unit of human integrin beta 2
EP0654532A4 (en) ANTIMUCOGLYCOPROTEIN MONOCLONAL ANTIBODIES.
AU5852094A (en) Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
HK1010986A (en) Humanized chimeric anti-icam-1 antibodies, methods of preparation and use
EP0520436A3 (en) Monoclonal antibody, method of production thereof and use thereof
GB9220228D0 (en) Reshaped monoclonal antibodies against an immunologlobulin isotype
EP0668923A4 (en) MONOCLONAL ANTIBODY.
GB9118013D0 (en) Monoclonal antibodies and their use
GB9210929D0 (en) Monoclonal antibodies and their use
GB9204514D0 (en) Monoclonal antibodies and their use
GB9210944D0 (en) Monoclonal antibodies and their use
GB9210930D0 (en) Monoclonal antibodies and their use